Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 701–800 of 1,000
Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases
Sharma, A., Singer, L., & Kumthekar, P. (2021) · Cancers · doi:10.3390/cancers14010017 · Cited by 6
Introductory Chapter: Protein Kinases as Promising Targets for Drug Design against Cancer
Bhatia, R., & Singh, R. K. (2021) · Biochemistry · doi:10.5772/intechopen.100315 · Cited by 6
Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Thomssen, C., Müller, V., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1724-9569 · Cited by 6
“The latest compound to demonstrate clear benefits in a randomised trial was the receptor tyrosine kinase inhibitor tucatinib, which improved progression-free survival and overall survival in a population largely with pertuzumab and T‐DM1 as prior treatment [23].”
Self-citationSurrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
Wright, K., Mittal, A., & Gyawali, B. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000984 · Cited by 6
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
Sposito, M., Belluomini, L., Pontolillo, L., Tregnago, D., Trestini, I., Insolda, J., Avancini, A., Milella, M., Bria, E., Carbognin, L., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101427 · Cited by 6
“…TKI, for residual invasive disease to reduce CNS relapse considering the intracranial response rate demonstrated in the metastatic setting [99], while in the ASTEFANIA trial (NCT04873362) T-DM1 is evaluated in combination with atezolizumab, a mAb anti-PD-L1, in a potential combined effect…”
BackgroundChehade, R., Nofech‐Mozes, S., Plotkin, A., Fan, K. Y., Das, S., Sahgal, A., Moravan, V., & Jerzak, K. J. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00487 · Cited by 6
Cheng, V. W. T., Heywood, R. M., Zakaria, R., Burger, R., Zucker, K., Kannan, S., Putra, M. A. R., Fitzpatrick, A., Doherty, G. J., Sanghera, P., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae140 · Cited by 6
Effective Personalization of Stereotactic Radiosurgery for Brain Metastases in the Modern Era
Edwards, D. M., & Kim, M. M. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000754 · Cited by 6
Aoki, Y., Nakayama, I., & Shitara, K. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01626-2 · Cited by 6
“In HER2-positive breast cancer, tucatinib in combination with Tmab and capecitabine showed a survival benefit in the phase III trial [79].”
Liu, J., Song, C., Yang, Y., Wang, X., Ni, M., Wang, X., Chen, L., Yang, H., Zhao, R., Xu, T., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3888 · Cited by 6
Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer
Janni, W. J., Kolberg, H., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marmé, F., et al. (2025) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2533-2783 · Cited by 6
Self-citationMortimer, J. E., Kruper, L. L., Cianfrocca, M. E., Lavasani, S. M., Liu, S., Patel, N. H., Sedrak, M. S., Smith, W., Stewart, D. B., Waisman, J. R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061984 · Cited by 6
“Our imaging research will utilize radiolabeled trastuzumab to predict for response to new agents such as fam-trastuzumab-deruxtecan and tucatinib [24,29].”
MethodLi, X., Wu, S., Zhang, L., Zhu, J. Y., & Xu, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5149 · Cited by 6
“005) compared to trastuzumab, capecitabine and placebo (43).”
BackgroundFabregat-Franco, C., Stradella, A., Navarro, V., Linares, J., Galdeano, M., Recalde, S., Velasco, R., Simó, M., Fernádez, A., Venthecourt, A. C., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02577-x · Cited by 6
“Moreover, more accurate treatment strategies have emerged in recent years [13, 14].”
BackgroundShaw, T., Lee, H., & Figlin, R. A. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3506.0306 · Cited by 6
Tailoring antiHer2 treatment strategies in breast cancer and beyond
Fedele, P., Sanna, V., Santoro, A. N., Iaia, M. L., & Fancellu, A. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100892 · Cited by 8
Ramakrishna, N. R., Anders, C. K., & Temin, S. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00364 · Cited by 6
Self-citationNew treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023
Banys‐Paluchowski, M., Krawczyk, N., Stickeler, E., Müller, V., & Fehm, T. N. (2022) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000830 · Cited by 7
“The approval trial HER2CLIMB randomly assigned patients with HER2-positive MBC previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), with or without brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine [3].”
Self-citationMohapatra, T., & Dixit, M. (2022) · ACS Omega · doi:10.1021/acsomega.2c05505 · Cited by 8
Meyer, J. A., DeChenne, S., Foerder, C. A., & Hengel, S. M. (2022) · Bioanalysis · doi:10.4155/bio-2022-0199 · Cited by 6
Advances in the Management of Metastatic Breast Cancer
Gradishar, W. J. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.5006 · Cited by 6
“The addition of tucatinib improved survival rates, including in patients with brainmetastases.(15) Antibody–drug conjugates such as T-DXd have also shown objective evidence of response in patients with brain metastases.”
BackgroundWu, Q., Sun, M.-S., Liu, Y., Ye, J., & Xu, L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05125-y · Cited by 6
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan
Neupane, N., Thapa, S., Bhattarai, A., Ahuja, K., Schlam, I. M., Mittal, A., Tolaney, S. M., & Tarantino, P. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01469-3 · Cited by 8
“…cancer, including monoclonal antibodies like trastuzumab [14, 15] and pertuzumab [16, 17]; TKIs like lapatinib [18], neratinib [19, 20], tucatinib [21], and pyrotinib [22]; and more recently antibody-drug conjugates (ADCs), including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan…”
Schettini, F., Giudici, F., & Generali, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23367 · Cited by 6
“Importantly, this study was conducted in a population pretreated with pertuzumab-based double blockade and T-DM1, including patients with stable or active brain metastases [6].”
BackgroundMethodInfluentialReceptor discordance in breast cancer brain metastases: when knowledge is power
Sammons, S. L., Swearingen, A. E. D. V., & Anders, C. K. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa131 · Cited by 6
Self-citationJerez, Y., Herrero, B., Arregui, M., Morón, B. I., Martín, M., & Echavarría, I. (2020) · Future Oncology · doi:10.2217/fon-2020-0046 · Cited by 6
Reevaluating the role of antibody–drug conjugates in the treatment of patients with brain metastases
Lin, N. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.021 · Cited by 6
Self-citationPonde, N. F., Agbor‐Tarh, D., Lago, L. D., Korde, L. A., Hilbers, F., Jackisch, C., Werner, O., Gelber, R. D., Jatoi, A., Dueck, A. C., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05915-9 · Cited by 6
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
Laakmann, E., Emons, J., Taran, F., Janni, W., Uhrig, S., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1286-2917 · Cited by 6
Self-citationJing, W., Zhou, M., Chen, R., Ye, X., Li, W., Su, X., Luo, J., Wang, Z., & Peng, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7915 · Cited by 6
“breast cancer (52), and with and without brain metastases (53).”
BackgroundEvaluating Cancer Drugs in Patients With Central Nervous System Metastases
Marur, S., Beaver, J. A., & Pazdur, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0180 · Cited by 6
Martinez‐García, M., Servitja, S., Quintela, N. V., Fernández, A. A., Jaime, A. B., de Ibargüen, B. C. S., Barco, S. D., Campelo, R. G., Sarrió, R. G., & Sepúlveda-Sánchez, J. M. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02803-0 · Cited by 7
“In the phase III HER2CLIMB trial [11], tucatinib, an oral tyrosine kinase inhibitor (TKI) with high selectivity for HER2, was combined with trastuzumab and capecitabine in 612 patients with previously treated HER2-positive metastatic breast cancer.”
BackgroundMerloni, F., Palleschi, M., Gianni, C., Sirico, M., Serra, R., Casadei, C., Sarti, S., Cecconetto, L., Menna, G. D., Mariotti, M., et al. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10312-3 · Cited by 6
“However, tucatinib showed important gastrointestinal toxicity which could potentially be enhanced by concomitant abdominal RT [66 ].”
Torelli, S., Agnihotri, V., Zhu, H., Wang, Z., Cheng, P. P., & Rhee, J. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01067-x · Cited by 5
“Similarly to lapatinib, clinical trials of ner-atinib and tucatinib have shown no increased incidence of cardiotoxicity [29–31].”
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
Camera, S., Rossari, F., Foti, S., Vitiello, F., Persano, M., Prinzi, F. L., COBELLI, F. D., Aldrighetti, L. A., Cascinu, S., Rimini, M., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01132-w · Cited by 5
“Several anti-HER2 therapies alone, combined, or added to chemotherapy have been evaluated in phase I and II trials with encouraging efficacy results in BTCs [19, 32, 40, 43–48].”
Miski, H., Krupa, K., Budzik, M. P., Deptała, A., & Badowska-Kozakiewicz, A. M. (2025) · Biomedicines · doi:10.3390/biomedicines13051153 · Cited by 5
“However, grade 3 or higher AE-like diarrhea or elevated aminotransferase levels were more common in the tucatinib group [98].”
Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer
Hesterberg, A. B., Wong, H. Y., Jackson, J., Antunovic, M., Rios, B. L., Watkins, E., Bergman, R. E., Davidson, B. A., Ginther, S. E., Graves, D. K., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187151 · Cited by 6
Liu, B., Yi, Z., Tian, C., Deng, J. K., Feng, R., Hu, Z.-Y., Xie, N., Li, Y., Zhao, J., Wu, T., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf277 · Cited by 5
Pan, H., Ji, W., Sun, Y., Li, F., Sun, C., Liu, M., Xu, H. L., Tao, J., Mao, X., Wang, C., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02409-2 · Cited by 5
Targeting the JAK/STAT Signaling Pathway in Breast Cancer: Leaps and Hurdles
Aho, S., Coste, C., Purcari, L., Trédan, O., Poulard, C., Méry, B., Boisvert, F., & Romancer, M. L. (2025) · Biomedicines · doi:10.3390/biomedicines13123061 · Cited by 7
“…of HER2+ cancers has also been revolutionized by the development of increasingly effective treatments targeting HER2, such as ADCs (e.g., Trastuzumab Deruxtecan and Trastuzumab Emtasine) [78–80] or tyrosine kinase inhibitors (such as Tucatinib in combination with Trastuzumab and Capecitabine) [81].”
Higashiyama, N., Nangia, J. R., Shafaee, M. N., Chen, N., Michael, B. L., Rimawi, M. F., & Hoyos, V. (2020) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2020.100034 · Cited by 5
“Small molecule tyrosine kinase inhibitors lapatinib, neratinib, and tucatinib have the strongest evidence of CNS penetration and activity against CNSm with overall responses in combination with capecitabine between 30 and 65% (Murthy et al., 2020; Bachelot et al., 2013; Petrelli et al., 2017; Freedman et al., 2019).”
Khanikar, D., Kamalasanan, K., Krishnamurthy, A., Hazarika, M., & Kataki, A. C. (2022) · Springer eBooks · doi:10.1007/978-981-19-5860-1_10 · Cited by 8
Passalacqua, M. I., Ciappina, G., Pietro, M. D., Spagnolo, C. C., Squeri, A., Granata, B., Muscolino, P., & Santarpía, M. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1126 · Cited by 6
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer
Salimbeni, B. T., Ferraro, E., Bielo, L. B., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_10 · Cited by 5
Self-citationKim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 6
Dai, Q., Feng, K., Liu, G., Cheng, H. W., Tong, X., Wang, X., Feng, L., & Wang, Y. P. (2024) · Targeted Oncology · doi:10.1007/s11523-023-01030-z · Cited by 5
“However, the advent and application of anti-HER2 drugs, such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-Dxd), have heralded a revolution in the treatment of HER2-positive BC patients [9–13].”
Chen, D., Xu, F., Lu, Y., Xia, W., Du, C., Xiong, D., Song, D. E., Shi, Y., Yuan, Z., Zheng, Q., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00646-2 · Cited by 7
“The HER2CLIMB trial has demonstrated that supplementing trastuzumab and capecitabine with tucatinib can extend median CNS – PFS to 9.9 months 10 , although adverse events (AEs) were responsible for death in 1.5% of participants 11 .”
InfluentialEr, A. B. B., & Er, İ. (2024) · Life · doi:10.3390/life14081040 · Cited by 5
“Breast cancer is a leading cause of cancer-related deaths among women worldwide, with 15–20% of cases being human epidermal growth factor receptor 2 (HER2)-positive [1].”
BackgroundNeratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
Conlon, N. T., Roche, S., Mahdi, A. F., Browne, A. L., Breen, L., Gaubatz, J., Meiller, J., O’Neill, F., O’Driscoll, L., Cremona, M., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102073 · Cited by 6
“Tucatinib was approved by the FDA in 2020 in combination with trastuzumab and capecitabine in HER2 + breast cancer [5].”
BackgroundMorris, C. D., Humphrey, C., & Dillon, P. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104513 · Cited by 6
Fang, W., Ma, X., & Liu, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2472493 · Cited by 5
Hoyek, C., Zheng-Lin, B., Jones, J. C., & Bekaii‐Saab, T. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472411 · Cited by 6
Lam, C. J. K., Varghese, D., Collins, J. M., Nordstrom, B. L., Murphy, B., Mehta, S., & Faherty, E. C. (2025) · The Oncologist · doi:10.1093/oncolo/oyae280 · Cited by 5
Shagisultanova, E. I., Parris, H. J., Liu, L., Giangiuli, S., Gao, D., Diamond, J. R., Acharya-Leon, R., Kabos, P., & Borges, V. F. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.06.004 · Cited by 6
Self-citationHurvitz, S. A., Simonelli, M., Yarza, R., Berz, D., Kitano, S., Conte, G. D., Acosta-Eyzaguirre, D., Uribe, B. D. D. S., Maier, D., Eržen, D., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2569553 · Cited by 7
“However, a survival benefit with an ADC and TKI combination has not yet been reported [8,23–25, Zongertinib is an irreversible TKI that selectively inhibits HER2, while sparing EGFR.”
Self-citationKim, J., Park, K., Im, S., Jung, K. H., Sohn, J., Lee, K. S., Kim, J. H., Yang, Y., & Park, Y. H. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05891-0 · Cited by 5
Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer
Eberst, L., Bailleux, C., & Bachelot, T. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000682 · Cited by 5
Self-citation« HER2-faible », un nouveau concept dans la prise en charge des cancers du sein
Deluche, É., & Vincent‐Salomon, A. (2021) · Bulletin du Cancer · doi:10.1016/s0007-4551(21)00631-7 · Cited by 5
Lerebours, F., Chalumeau, C., Carton, M., Eeckhoutte, A., Ballet, S., Vincent‐Salomon, A., Vuagnat, P., Bellesœur, A., Pierga, J.-Y., Stern, M.-H., et al. (2022) · Cancers · doi:10.3390/cancers14092114 · Cited by 5
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
Singh, J. C., & Lichtman, S. M. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00889-9 · Cited by 5
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
Cunningham, N., Shepherd, S. T. C., Mohammed, K., Lee, K. A., Allen, M. J., Johnston, S. R. D., Kipps, E., McGrath, S., Noble, J. L., Parton, M., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06703-3 · Cited by 5
“Notably, the study included patients with active or untreated CNS disease, demonstrating a similar magnitude of benefit in these patients, presenting this as a favourable second- or third-line option, in particular for patients with brain metastases, especially as the combination was very well-tolerated [25].”
BackgroundSelf-citationDoğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P. M., & Aydıner, A. (2023) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2023.2022-12-4 · Cited by 5
“In a study evaluating tucatinib, a new generation tyrosine kinase inhibitor, the addition of tucatinib to trastuzumab and capecitabine improved survival compared to placebo in patients with previously treated HER2-positive metastatic breast cancer (16).”
Zhang, N., Xiang, Y., Shao, Q., Wu, J., Liu, Y., Long, H., Tao, D., & Zeng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1102853 · Cited by 8
Wu, F., Chen, M., Wang, L., Li, N., Wu, X., Chen, X., Yi, H., Li, C., Lin, L., Chen, K., et al. (2023) · Current Cancer Drug Targets · doi:10.2174/0115680096248592231016065117 · Cited by 5
Neurological Complications of Targeted Therapies and Immunotherapies for Cancer
McFaline-Figueroa, J. R., & Lee, E. Q. (2021) · Current Treatment Options in Neurology · doi:10.1007/s11940-021-00663-7 · Cited by 6
Rabadi, L. S. A., Cook, M. M., Kaempf, A. J., Saraceni, M. M., Savin, M. A., & Mitri, Z. I. (2021) · BMC Cancer · doi:10.1186/s12885-021-08894-2 · Cited by 5
Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
Jones, J., Ciombor, K., Wu, C., Bekaii‐Saab, T., & Strickler, J. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0654 · Cited by 7
Feng, M., Yang, Y., Liao, W., & Li, Q. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.03.002 · Cited by 5
Neurologic complications of breast cancer
Atkins, S., & Zimmer, A. S. (2022) · Cancer · doi:10.1002/cncr.34518 · Cited by 5
de Bernardi, A., Bachelot, T., & Larrouquère, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210873 · Cited by 7
Self-citationPerachino, M., Arecco, L., Martelli, V., & Lambertini, M. (2020) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-34 · Cited by 5
Peterson, L. E. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12155523 · Cited by 8
“Tucatinib (Rank 11, BE=-9, B11652) is indicated for HER-2 positive metastatic breast cancer[68].”
BackgroundDiscussion of ABC7 Consensus and German Recommendations
Untch, M., Ditsch, N. C., Fasching, P. A., Busch, S., Ettl, J., Haidinger, R., Harbeck, N., Jackisch, C., Lüftner, D., Müller, L., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2263-5152 · Cited by 5
“The evidence is less robust than evidence from a randomized trial such as HER2Climb with tucatinib/capecitabine/trastuzumab [27].”
BackgroundSelf-citationBeyond Primary HER2 Expression: Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis
Das, G., Wong, S. T. C., & Zhao, H. (2024) · Cancers · doi:10.3390/cancers16203525 · Cited by 5
“…when contrasted with prior HER2-targeted therapies, which have shown variable efficacy due to poor penetration of the blood–brain barrier [2–4], including HER2-directed antibodies such as trastuzumab and pertuzumab, antibody–drug conjugates like T-DM1, and small-molecule tyrosine kinase…”
BackgroundSato, S., Nakayama, I., & Shitara, K. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2551748 · Cited by 4
“In HER2-positive breast cancer, the survival benefit of combining tucatinib with Tmab and capecitabine was confirmed in a phase III trial [96].”
Maximal feasible resection versus hybrid therapy in spinal metastases: an updated narrative review
Shen, Z. Z., Wang, P., Zhao, Y., Xin, Y., Zhang, H., Zhang, X., Li, B., Xu, W., & Xiao, J. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04009-4 · Cited by 4
“In addition, with the advent of the era of targeted therapy and immunotherapy [9–12] and the progress of surgical technologies [13, 14], the life expectancy of particular cancer patients has been prolonged, which in turn may increase the likelihood of local recurrence following surgery [15].”
Chen, F., & Bradbury, M. S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03631-4 · Cited by 4
“Despite advancements in therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer, including trastuzumab [1], pertuzumab [1, 2], and small-molecule inhibitors, such as tucatinib [3], several clinical challenges remain that can limit treatment effectiveness.”
Chougoni, K. K., Park, H., Damle, P. K., Mason, T., Cheng, B., Dcona, M. M., Szomju, B. B., Dozmorov, M. G., Idowu, M. O., & Grossman, S. R. (2023) · Oncogenesis · doi:10.1038/s41389-023-00498-8 · Cited by 4
“…complexes in oncogenic signaling evidenced by the success of pertuzumab that targets ErbB2/3 heterodimerization in breast cancer refractory to trastuzumab [22], and; (3) the improvement in survival seen with dual targeting of ErbB2/3 with trastuzumab and the ErbB2-speci fi c TKI tucatinib [23].”
Activity of capecitabine for central nervous system metastases from breast cancer
Gouveia, M. C., Filho, C. M. T. H., Moreno, R., Alves, H. C. B. R., Ayres, A. S., Testa, L., & Bonadio, R. C. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1638 · Cited by 4
“Despite encouraging data demonstrating an intracranial response rate of up to 73.3% for trastuzumab deruxtecan in a phase II study, costs and access still limit the use of these drugs in clinical practice [5, 6].”
BackgroundInfluentialABC7 Consensus: Assessment by a German Group of Experts
Ditsch, N., Untch, M., Fasching, P. A., Busch, S., Ettl, J., Haidinger, R., Jackisch, C., Lüftner, D., Müller, L., Müller, V., et al. (2024) · Breast Care · doi:10.1159/000535997 · Cited by 5
“The evidence is less robust than in a prospective randomized trial, such as the HER2CLIMB with tucatinib/capecitabine/trastuzumab [24] – this should be considered when deciding on the therapy for active BM.”
BackgroundSelf-citationInoue, K., Nakamura, Y., Caughey, B. A., Zheng-Lin, B., Ueno, M., Furukawa, M., Kawamoto, Y., Itoh, S., Umemoto, K., Sudo, K., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00718 · Cited by 8
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer
Lorini, L., Gili, R., Resteghini, C., Gerosa, R., Cecchi, L. G., Gurizzan, C., Zambelli, A., Zucali, P. A., & Bossi, P. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107296 · Cited by 4
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
Li, J., Liu, Y., Wang, S., Wang, S., Zhang, S., Li, M., Yang, J., Mo, X., Yan, M., Geng, C., et al. (2025) · Translational Breast Cancer Research · doi:10.21037/tbcr-25-34 · Cited by 5
“The HER2CLIMB study (27) demonstrated that tucatinib plus trastuzumab and capecitabine significantly prolonged PFS and OS, especially in patients with brain metastases.”
New therapies for brain metastases: an update
Porte, M., & Massard, C. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001195 · Cited by 5
Durrani, S., Al-Ghamdi, A. A., Al-Bugawi, A., Alkhammash, A., Alhawish, M. K., Dabour, K., Al-Obaisi, Y., & Alrashidi, S. (2025) · BMC Cancer · doi:10.1186/s12885-025-14844-z · Cited by 4
“…hand, the combination of trastuzumab and capecitabine with tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, resulted in more favorable outcomes in the overall survival and progression-free survival in heavily pretreated HER2-positive mBC patients, including those with BM [57].”
Trastuzumab Emtansine: a Game Changer in HER2-Positive Early Breast Cancer
Mano, M. S. (2020) · Future Oncology · doi:10.2217/fon-2020-0219 · Cited by 4
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
Semiglazova, Т. Y., Sharashenidze, S. M. S., Kerimova, S. N. K., Klimenko, V. V., Malygin, A. Y., Dashyan, G. A., Палтуев, Р. М., Семиглазов, В. В., Криворотько, П. В., Новиков, С. Н., et al. (2021) · Tumors of female reproductive system · doi:10.17650/1994-4098-2021-17-1-27-34 · Cited by 4
Liwski, C. R., Castonguay, M., Barnes, P. J., Rayson, D., & Bethune, G. C. (2022) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2022.151953 · Cited by 4
Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases
Dhakal, A., Swearingen, A. E. D. V., O'Regan, R. M., & Anders, C. K. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01011-w · Cited by 4
Self-citationBHARGAVA, P. G., Rathnasamy, N., Shenoy, R., Gulia, S., Bajpai, J., Ghosh, J., Rath, S., Budrukkar, A. N., Shet, T. M., Patil, A. J., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00126 · Cited by 5
“It is likely that future studies in patients with HER2-positive disease and central nervous system metastases will be prospective, and such patients will be systematically included in clinical trials, as was done in the HER2CLIMB trial, which has led to significant improvement in outcomes.(39,40)”
BackgroundPrinciples of systemic anticancer therapy (SACT)
Roy, D., & Ahmed, S. I. (2024) · Surgery (Oxford) · doi:10.1016/j.mpsur.2023.12.015 · Cited by 4
Yuan, Y., Liu, X., Xu, G., Zhang, J., Chen, L., & Long, X. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102901 · Cited by 4
Capecitabine and stereotactic radiation in the management of breast cancer brain metastases
Mills, M. N., Naz, A., Thawani, C., Walker, C., Figura, N. B., Kushchayev, S. V., Oliver, D. E., Etame, A. B., Yu, H.-H. M., Robinson, T. J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08302-9 · Cited by 4
“In addition, the recently reported HER2CLIMB study combined capecitabine with the oral TKI tucatinib and trastuzumab [21].”
BackgroundRe‐thinking therapeutic development for CNS metastatic disease
Saberian, C., & Davies, M. A. (2021) · Experimental Dermatology · doi:10.1111/exd.14413 · Cited by 4
A Review of Therapeutic Antibodies in Breast Cancer
Eini, M., Zainodini, N., Montazeri, H., Mirzabeigi, P., & Tarighi, P. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31864 · Cited by 4
“Over the last two decades, monoclonal antibodies have become an interesting therapeutic option to treat different types of breast cancer because of their specific targeting ability and overall response rate (14,15).”
BackgroundBalch, S., Vaz-Luís, I., Li, T., Tayob, N., Jain, E., Helvie, K. E., Buendia-Buendia, J. E., Shannon, E. E., Isakoff, S. J., Tung, N., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06329-x · Cited by 4
Self-citationImmune response pathways enriched in breast cancer samples with brain metastasis
Wang, P., Sun, Z., Zhang, Z., & Yin, Q. (2021) · Gland Surgery · doi:10.21037/gs-21-745 · Cited by 4
Ghafouri, S. R., Guvvala, S. L., Jones, C., & Philipovskiy, A. V. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002298 · Cited by 4
Zhu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.918759 · Cited by 4
An attention mechanism-based LSTM network for cancer kinase activity prediction
Danishuddin, M., Kumar, V., Lee, G., Yoo, J., Ro, H., & Lee, K. W. (2022) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2022.2109062 · Cited by 4
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.